Abstract:
The invention disclosed herein relates to an enantioselective process for preparation of biologically active (R) and (S) enantiomers of sex pheromones of the long-tailed Mealybug with high enantiopurity having significant biological activity. Further, the invention provides absolute configuration of synthesized R and S enantiomers.(I)
Abstract:
The present invention concerns a process of carbonylation of poly-unsaturated diene with high selectivity for the preparation of a β,γ - unsaturated carboxylic acid or ester in the presence of water or alcohol and catalyzed by [PdCl 2 P 2 ] complex wherein P 2 is two mono or one bidendate phosphine ligand.
Abstract translation:本发明涉及一种在水或醇存在下以高选择性制备γ-不饱和羧酸或酯并通过[PdCl 2 P 2]络合物催化的多不饱和二烯的羰基化方法,其中P2是两个单 或一种铋膦配体。
Abstract:
The invention relates to a process for the isomerization of unsaturated fatty acids or esters or amides thereof, said process comprising reacting: (a) an unsaturated fatty acid or ester or amide thereof; (b) a source of Pd; (c) a bidentate diphosphine of formula I, R1R2 > P1-R-P2
Abstract:
Provided herein are water-soluble, functionalized fullerenes, and processes for producing water-soluble, functionalized fullerenes. The process includes sulfonating a fullerene in an acidic solution comprising sulfuric acid to produce a sulfonated fuUerene, isolating the sulfonated fullerene from the acidic solution without neutralizing the acidic solution, reacting the sulfonated fullerene with hydrogen peroxide to form a reaction product, and isolating a polyhydroxylated fullerene from the reaction product produced from reacting the sulfonated fullerene with the hydrogen peroxide. The process of producing water-soluble fullerenes further includes functionalizing a polyhydroxylated fullerene with one or more pendant functional groups by reacting the polyhydroxylated fullerene with one or more functional group precursors.
Abstract:
A method for preparing docosahexaenoic acid (DHA). The method comprises coupling a compound represented by Formula I with a compound represented by Formula II followed by partial hydrogenation to obtain a compound represented by Formula III. The compound represented by Formula III acts as a DHA precursor and thus can be hydrolysed to obtain DHA. Novel starting materials represented by Formula I and Formula II, and synthetic routes for preparing the same are also provided.
Abstract:
Provided herein are water-soluble, functionalized fullerenes, and processes for producing water-soluble, functionalized fullerenes. The process includes sulfonating a fullerene in an acidic solution comprising sulfuric acid to produce a sulfonated fullerene, isolating the sulfonated fullerene from the acidic solution without neutralizing the acidic solution, reacting the sulfonated fullerene with hydrogen peroxide to form a reaction product, and isolating a polyhydroxylated fullerene from the reaction product produced from reacting the sulfonated fullerene with the hydrogen peroxide. The process of producing water-soluble fullerenes further includes functionalizing a polyhydroxylated fullerene with one or more pendant functional groups by reacting the polyhydroxylated fullerene with one or more functional group precursors.
Abstract:
The invention relates to a procedure for stabilising polyunsaturated fatty acids with selective reducing agents. In particular, the invention relates to a process of preparation of polyunsaturated acids of the omega-3 series, as such or in the form of esters, which comprises treatment of fish oil or a mixture of acids with urea, and subsequent treatment with a metal hydride, preferably sodium borohydride. The polyunsaturated fatty acids of greatest interest present in fish oil are docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).
Abstract:
Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.
Abstract:
Omega-3 lipid compounds of the general formula (1): wherein P represents a hydrogen atom, Formulas (a), (b), (c) or (d) and (e), Y is a C14-C22 alkenyl group with at least one double bond, having E and/or Z, configuration;., or any pharmaceutically acceptable complex, solvate, salt or pro-drug thereof, with the proviso that R1 and R2 are not simultaneously a hydrogen atom. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments, in particular for the treatment of cardiovascular and metabolic diseases.
Abstract:
This invention relates generally to olefin metathesis, and more particularly relates to the ring-opening, ring insertion cross-metathesis of cyclic olefins with internal olefins such as seed oils and the like. In one embodiment, a method is provided for carrying out a catalytic ring-opening cross-metathesis reaction, comprising contacting at least one olefinic substrate with at least one cyclic olefin as a cross metathesis partner, in the presence of a ruthenium alkylidene olefin metathesis catalyst under conditions effective to allow ring insertion cross metathesis whereby the cyclic olefin is simultaneously opened and inserted into the olefinic substrate. The invention has utility in the fields of catalysis, organic synthesis, and industrial chemistry.